Human TGFBR2 Antibody Pair - BSA and Azide free (ab253617)
Key features and details
- Unconjugated capture and detector antibodies
- Adaptable to any antibody pair-based assay format
- Antibody concentration ~ 1 mg/ml
- BSA and azide free buffer - ready for conjugation
- Reacts with: Human
Overview
-
Product name
Human TGFBR2 Antibody Pair - BSA and Azide free
See all TGF beta Receptor II kits -
Assay type
ELISA set -
Range
15.6 pg/ml - 1000 pg/ml -
Species reactivity
Reacts with: Human -
Product overview
- Human TGFBR2 Antibody Pair is a matched pair of unconjugated recombinant rabbit monoclonal capture and detection antibodies used to quantify Human TGFBR2 in sandwich ELISAs and many other pair-based applications.
- The pair can be used in variety of assays and platforms including but not limited to:
- - Sandwich ELISA
- - FRET/TR-FRET/HTR
- - Meso Scale Discovery® (MSD®)
- - Luminex® and bead-based assays
- - AlphaLISA®/AlphaScreen®
- - DELFIA® immunoassays
- - Simoa® and Single Molecule Counting (SMC™) immunoassays
- - Multiplex
- Our antibody pairs are supplied in a carrier-free format that is conjugation-ready:
- - Buffer free of BSA, sodium azide, and glycerol for higher conjugation efficiency.
- - Concentration of ~1 mg/ml as measured by the protein A280 method.
- Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with
- We can label antibodies for you: get in touch today to discuss how we can help accelerate your assay development with custom conjugation services.
- Pairs are screened in biological samples, including plasma and serum, to ensure specificity in complex samples.
- Please note:
- The recommended antibody orientation is based on internal optimization in sandwich ELISA. Antibody orientation is assay dependent and needs to be optimized for each assay type.
- The range provided for this antibody pair is based on initial sandwich ELISA validation data using recombinant protein. Performance and range of the antibody pair will depend on the specific characteristics of your assay, including standard protein selection.
- We guarantee the product works in sandwich ELISA, but we do not guarantee the sensitivity or dynamic range of the antibodies in other assays.
- Antibody properties:
- Capture antibody: recombinant rabbit monoclonal (unconjugated) – 100 µg
- Detector antibody: recombinant rabbit monoclonal (unconjugated) - 100 µg
- Concentration: ~1 mg/ml
- Storage buffer: 100% PBS
- Form: Liquid
- Isotype: IgG
- Recombinant monoclonal antibodies offer several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
- For more information see here.
- Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
- Meso Scale Discovery and MSD are registered trademarks of Meso Scale Diagnostics, LLC.
- Luminex is a trademark of Luminex Corporation, registered in the US and other countries.
- AlphaLISA, AlphaScreen, and DELFIA are registered trademarks of PerkinElmer, Inc.
- Simoa is a registered trademark of Quanterix, Inc.
- SMC is a registered trademark of Merck KGaA, Darmstadt, Germany.
-
Tested applications
Suitable for: Sandwich ELISAmore details -
Platform
Reagents
Properties
-
Storage instructions
Store at +4°C. Please refer to protocols. -
Carrier free
Yes -
Components Identifier 10 x 96 tests Human TGFBR2 Capture Antibody (unconjugated) — Human TGFBR2 Detector Antibody (unconjugated) — -
Research areas
-
Function
Transmembrane serine/threonine kinase forming with the TGF-beta type I serine/threonine kinase receptor, TGFBR1, the non-promiscuous receptor for the TGF-beta cytokines TGFB1, TGFB2 and TGFB3. Transduces the TGFB1, TGFB2 and TGFB3 signal from the cell surface to the cytoplasm and is thus regulating a plethora of physiological and pathological processes including cell cycle arrest in epithelial and hematopoietic cells, control of mesenchymal cell proliferation and differentiation, wound healing, extracellular matrix production, immunosuppression and carcinogenesis. The formation of the receptor complex composed of 2 TGFBR1 and 2 TGFBR2 molecules symmetrically bound to the cytokine dimer results in the phosphorylation and the activation of TGFRB1 by the constitutively active TGFBR2. Activated TGFBR1 phosphorylates SMAD2 which dissociates from the receptor and interacts with SMAD4. The SMAD2-SMAD4 complex is subsequently translocated to the nucleus where it modulates the transcription of the TGF-beta-regulated genes. This constitutes the canonical SMAD-dependent TGF-beta signaling cascade. Also involved in non-canonical, SMAD-independent TGF-beta signaling pathways. -
Involvement in disease
Defects in TGFBR2 are the cause of hereditary non-polyposis colorectal cancer type 6 (HNPCC6) [MIM:614331]. Mutations in more than one gene locus can be involved alone or in combination in the production of the HNPCC phenotype (also called Lynch syndrome). Most families with clinically recognized HNPCC have mutations in either MLH1 or MSH2 genes. HNPCC is an autosomal, dominantly inherited disease associated with marked increase in cancer susceptibility. It is characterized by a familial predisposition to early onset colorectal carcinoma (CRC) and extra-colonic cancers of the gastrointestinal, urological and female reproductive tracts. HNPCC is reported to be the most common form of inherited colorectal cancer in the Western world, and accounts for 15% of all colon cancers. Cancers in HNPCC originate within benign neoplastic polyps termed adenomas. Clinically, HNPCC is often divided into two subgroups. Type I: hereditary predisposition to colorectal cancer, a young age of onset, and carcinoma observed in the proximal colon. Type II: patients have an increased risk for cancers in certain tissues such as the uterus, ovary, breast, stomach, small intestine, skin, and larynx in addition to the colon. Diagnosis of classical HNPCC is based on the Amsterdam criteria: 3 or more relatives affected by colorectal cancer, one a first degree relative of the other two; 2 or more generation affected; 1 or more colorectal cancers presenting before 50 years of age; exclusion of hereditary polyposis syndromes. The term "suspected HNPCC" or "incomplete HNPCC" can be used to describe families who do not or only partially fulfill the Amsterdam criteria, but in whom a genetic basis for colon cancer is strongly suspected. HNPCC6 is a type of colorectal cancer complying with the clinical criteria of HNPCC, except that the onset of cancer was beyond 50 years of age in all cases.
Defects in TGFBR2 are a cause of esophageal cancer (ESCR) [MIM:133239].
Defects in TGFBR2 are the cause of Loeys-Dietz syndrome type 1B (LDS1B) [MIM:610168]. LDS1 is an aortic aneurysm syndrome with widespread systemic involvement. The disorder is characterized by arterial tortuosity and aneurysms, craniosynostosis, hypertelorism, and bifid uvula or cleft palate. Other findings include exotropy, micrognathia and retrognathia, structural brain abnormalities, intellectual deficit, congenital heart disease, translucent skin, joint hyperlaxity and aneurysm with dissection throughout the arterial tree.
Defects in TGFBR2 are the cause of Loeys-Dietz syndrome type 2B (LDS2B) [MIM:610380]. An aortic aneurysm syndrome with widespread systemic involvement. Physical findings include prominent joint laxity, easy bruising, wide and atrophic scars, velvety and translucent skin with easily visible veins, spontaneous rupture of the spleen or bowel, diffuse arterial aneurysms and dissections, and catastrophic complications of pregnancy, including rupture of the gravid uterus and the arteries, either during pregnancy or in the immediate postpartum period. LDS2 is characterized by the absence of craniofacial abnormalities with the exception of bifid uvula that can be present in some patients. Note=TGFBR2 mutations Cys-460 and His-460 have been reported to be associated with thoracic aortic aneurysms and dissection (TAAD). This phenotype, also known as thoracic aortic aneurysms type 3 (AAT3), is distinguised from LDS2B by having aneurysms restricted to thoracic aorta. As individuals carrying these mutations also exhibit descending aortic disease and aneurysms of other arteries (PubMed:16027248), they have been considered as LDS2B by the OMIM resource. -
Sequence similarities
Belongs to the protein kinase superfamily. TKL Ser/Thr protein kinase family. TGFB receptor subfamily.
Contains 1 protein kinase domain. -
Post-translational
modificationsPhosphorylated on a Ser/Thr residue in the cytoplasmic domain. -
Cellular localization
Cell membrane. - Information by UniProt
-
Alternative names
- AAT3
- FAA3
- LDS1B
see all -
Database links
- Entrez Gene: 7048 Human
- Omim: 190182 Human
- SwissProt: P37173 Human
- Unigene: 604277 Human
- Unigene: 82028 Human
Images
-
To learn more about the advantages of recombinant antibodies see here.